Chinese Academy of Sciences

Suzhou Suplead Life Sciences Co., Ltd.

Suzhou Institute of Materia Medica

Yaxi Yang

Bing Zhou

Hualiang Jiang

Cheng Luo

Gang Qiao

Wei Tang

Shijie Chen

Xiangbo Yang

Xinjun Wang

Huijin Feng

Mengying Gao

Huimin Lu

Senhao Xiao

Hong Ding

Yuanyuan Zhang

Shili Wan

Rukang Zhang

Wenchao Lu

Lianghe Mei

Zizhou Li

Daohai Du

Disclosed is a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by the general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereoisomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising same and use thereof in the treatment of various HAT-related diseases or conditions.

Histone acetyltransferase (HAT) inhibitor and use thereof

The present invention relates to a heterocyclic amide inhibiting RIP1 kinase and the use thereof, and specifically, to a compound of formula I, its pharmaceutically acceptable salts, stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers, racemates, polymorphs, solvates or isotopically labeled compounds, a pharmaceutical composition comprising the compound, and the pharmaceutical use thereof. The compound is particularly effective for treatment of diseases or disorders mediated by RIP1 kinase.

Heterocyclic amide for inhibiting RIP1 kinase and uses thereof

The present invention relates to a heterocyclic amide inhibiting RIP1 kinase and the use thereof, and specifically, to a compound of formula I, its pharmaceutically acceptable salts, stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers, racemates, polymorphs, solvates or isotopically labeled compounds, a pharmaceutical composition comprising the compound, and the pharmaceutical use thereof. The compound is particularly effective for treatment of diseases or disorders mediated by RIP1 kinase. 

The present invention relates to a bromodomain inhibitor. Provided are a compound represented by general formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, atropisomer, racemate, polymorph, solvate, or isotopically labeled compound (including deuterium substitution) thereof, a preparation method of the same, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof. 

Bromodomain inhibitor compound and use thereof

The present invention provides a compound represented by formula I, pharmaceutically acceptable salts, enantiomers, diastereomers or racemates thereof, the preparation method thereof, the pharmaceutical composition comprising the same, and the use thereof in the preparation of a medicament for treating a disease or condition mediated by EED and/or PRC2. The compound of the present invention can be used treating PRC2-mediated diseases or conditions. 

Triazolopyrimidine, triazolopyridine compounds, and the composition thereof for treating PRC2-mediated diseases

Growing community of inventors

Shanghai, China

Yaxi Yang